Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.
Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas. However, the clinical and biological significance of such aberrations and their subclonal distribution are poorly understood. Here, we present th...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826304653679132672 |
|---|---|
| author | Knight, S Yau, C Clifford, R Timbs, A Sadighi Akha, E Dréau, H Burns, A Ciria, C Oscier, D Pettitt, A Dutton, S Holmes, C Taylor, J Cazier, J Schuh, A |
| author_facet | Knight, S Yau, C Clifford, R Timbs, A Sadighi Akha, E Dréau, H Burns, A Ciria, C Oscier, D Pettitt, A Dutton, S Holmes, C Taylor, J Cazier, J Schuh, A |
| author_sort | Knight, S |
| collection | OXFORD |
| description | Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas. However, the clinical and biological significance of such aberrations and their subclonal distribution are poorly understood. Here, we present the first genome-wide array based study of pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) that uses the computational statistical tool OncoSNP. We show that quantification of the proportion of copy number alterations (CNAs) and copy neutral loss of heterozygosity regions (cnLOHs) in each sample is feasible. Furthermore, we (i) reveal complex changes in the subclonal architecture of paired samples at relapse compared with pre-treatment, (ii) provide evidence supporting an association between increased genomic complexity and poor clinical outcome (iii) report previously undefined, recurrent CNA/cnLOH regions that expand or newly occur at relapse and therefore might harbor candidate driver genes of relapse and/or chemotherapy resistance. Our findings are likely to impact on future therapeutic strategies aimed towards selecting effective and individually tailored targeted therapies. |
| first_indexed | 2024-03-07T06:21:04Z |
| format | Journal article |
| id | oxford-uuid:f2bbcae2-7d7a-4022-9cbb-b157abc70ddc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:21:04Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:f2bbcae2-7d7a-4022-9cbb-b157abc70ddc2022-03-27T12:06:16ZQuantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f2bbcae2-7d7a-4022-9cbb-b157abc70ddcEnglishSymplectic Elements at Oxford2012Knight, SYau, CClifford, RTimbs, ASadighi Akha, EDréau, HBurns, ACiria, COscier, DPettitt, ADutton, SHolmes, CTaylor, JCazier, JSchuh, AGenome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas. However, the clinical and biological significance of such aberrations and their subclonal distribution are poorly understood. Here, we present the first genome-wide array based study of pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) that uses the computational statistical tool OncoSNP. We show that quantification of the proportion of copy number alterations (CNAs) and copy neutral loss of heterozygosity regions (cnLOHs) in each sample is feasible. Furthermore, we (i) reveal complex changes in the subclonal architecture of paired samples at relapse compared with pre-treatment, (ii) provide evidence supporting an association between increased genomic complexity and poor clinical outcome (iii) report previously undefined, recurrent CNA/cnLOH regions that expand or newly occur at relapse and therefore might harbor candidate driver genes of relapse and/or chemotherapy resistance. Our findings are likely to impact on future therapeutic strategies aimed towards selecting effective and individually tailored targeted therapies. |
| spellingShingle | Knight, S Yau, C Clifford, R Timbs, A Sadighi Akha, E Dréau, H Burns, A Ciria, C Oscier, D Pettitt, A Dutton, S Holmes, C Taylor, J Cazier, J Schuh, A Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. |
| title | Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. |
| title_full | Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. |
| title_fullStr | Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. |
| title_full_unstemmed | Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. |
| title_short | Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. |
| title_sort | quantification of subclonal distributions of recurrent genomic aberrations in paired pre treatment and relapse samples from patients with b cell chronic lymphocytic leukemia |
| work_keys_str_mv | AT knights quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT yauc quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT cliffordr quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT timbsa quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT sadighiakhae quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT dreauh quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT burnsa quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT ciriac quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT oscierd quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT pettitta quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT duttons quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT holmesc quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT taylorj quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT cazierj quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia AT schuha quantificationofsubclonaldistributionsofrecurrentgenomicaberrationsinpairedpretreatmentandrelapsesamplesfrompatientswithbcellchroniclymphocyticleukemia |